Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00103701
Study type Interventional
Source Bristol-Myers Squibb
Contact
Status Completed
Phase Phase 1
Start date November 2003
Completion date March 2006

See also
  Status Clinical Trial Phase
Completed NCT01725204 - Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia Phase 2
Completed NCT01856283 - Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells Phase 2
Completed NCT00048672 - Therapy of Early Chronic Phase CML With Gleevec Phase 2
Recruiting NCT02767063 - Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) Phase 1/Phase 2
Terminated NCT01827930 - Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response Phase 3
Terminated NCT01488253 - Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants Phase 2
Withdrawn NCT01650467 - Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms N/A
Completed NCT02888964 - Pioglityazone and Imatinib for CML Patients Phase 2
Active, not recruiting NCT03239886 - Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log N/A
Terminated NCT03807479 - Study in Patients With Chronic Leukemia Phase 2